By establishing a “Human-in-the-Loop” drug discovery platform that integrates humans, AI, and robots, Astellas has succeeded in reducing the time it takes from hit compound to acquisition of a drug candidate compound by approximately 70% in successful cases. The key to speeding up the drug discovery process is utilizing AI and robots together with researchers’ input, ideas, and comprehensive judgment. Our platform revolves around a DMTA cycle—” Design,” “Make” the compound, “Test” the effects, and “Analyze.” Based on the result, we can further design a better compound.
In order to utilize this platform for new modalities such as cells and genes, we developed Mahol-A-Ba, based on Maholo—a robot that had already been introduced at the Tsukuba Research Center to utilize iPS cells for drug discovery.
For this story:
source
